Monopar Therapeutics Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing; it does not provide standalone fourth-quarter results. The company is a clinical-stage biopharmaceutical developer and reported no product revenue.
Business context and pipeline
- Validive: Lead candidate in a global Phase 2b/3 VOICE trial to prevent chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer. Interim analysis was anticipated in mid-2022; as of March 11, 2022, 44 sites were active and enrolling.
- Camsirubicin: Began a U.S. Phase 1b dose-escalation trial for advanced soft tissue sarcoma in 2021. Management planned a subsequent GEIS-led Phase 2 comparison with doxorubicin, subject to completion of Phase 1b.
- MNPR-101 and radioimmunotherapeutics: Preclinical antibody program and partnered RIT/diagnostic development with NorthStar; the company was evaluating a first-in-human study.
- MNPR-202: Preclinical camsirubicin analog program with Cancer Science Institute of Singapore.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $6.49 million | $4.07 million |
| General and administrative expense | $2.63 million | $2.44 million |
| Total operating expenses | $9.13 million | $6.51 million |
| Net loss | $9.10 million | $6.30 million |
| Basic and diluted loss per share | $0.73 | $0.58 |
| Net cash used in operating activities | $7.32 million | $4.66 million |
| Net cash provided by financing activities | $10.88 million | $8.18 million |
- Cash and cash equivalents were $20.30 million at year-end, versus $16.74 million a year earlier. Current assets were $20.52 million and current liabilities $1.58 million; total liabilities were also $1.58 million. The filing reports no debt balance.
- Stockholders’ equity was $18.94 million and accumulated deficit was $41.29 million at December 31, 2021.
- The company raised $10.93 million net from common-stock sales under its at-the-market program in 2021, issuing 1.10 million shares. The program’s maximum offering amount was reached in the first quarter of 2021.
Material changes versus 2020
- Net loss increased by $2.80 million, as operating expenses rose $2.62 million. R&D increased $2.43 million, primarily from Validive trial activity and manufacturing, personnel costs, and preclinical work; G&A rose $0.19 million.
- Operating cash use increased $2.66 million, mainly from higher R&D and G&A spending. Financing proceeds increased, largely from the ATM stock sales.
- 2020 included $122,400 of PPP loan forgiveness income; there was no comparable income in 2021.
Outlook, risks and unusual items
- Management estimated available funds would support planned operations at least through March 31, 2023, based on assumptions that could prove incorrect. It stated that additional funding would be needed to complete VOICE—including a possible second confirmatory Phase 3—and to advance camsirubicin and other programs. VOICE funding needs were described as millions or tens of millions of dollars, depending on a partnership or collaboration.
- Management planned to pursue financing or a suitable partner within 12 months. It warned that without adequate funding or a satisfactory partnership, the company could delay or discontinue one or more programs. Financing could dilute shareholders or require the company to relinquish rights.
- Key risks include clinical-trial failure or delay, patient enrollment, regulatory uncertainty, dependence on contract manufacturers and research organizations, supply-chain and shipping costs, COVID-19 impacts, and potential effects of the Russia-Ukraine conflict. The company also faces competition, intellectual-property risks, and reimbursement and pricing uncertainty.
- Validive’s prior Phase 2 OPC subgroup data showed a 26.3 percentage-point lower SOM incidence at 100 μg versus placebo (38.9% versus 65.2%; p=0.09), a result that was not statistically significant. Future trial success and regulatory approval remain uncertain.
- The Onxeo Validive license includes potential milestones of up to $108 million and royalties of 5%–10% of net sales. No milestones or royalties were incurred in 2021. No material legal proceedings were reported.
- Management assessed internal control over financial reporting and disclosure controls as effective at year-end. The independent auditor issued an unqualified opinion on the financial statements and did not audit internal control effectiveness.
Most important facts for investors to verify
- Current cash, actual cash burn, and whether financing has been secured beyond the runway estimate disclosed in this filing.
- VOICE interim-analysis timing, enrollment, statistical results, and whether another confirmatory Phase 3 trial is required.
- Camsirubicin Phase 1b safety, dose-escalation progress, and funding and design for the proposed Phase 2 trial.
- Any partnership, licensing, or financing terms, including dilution and rights surrendered.
- Share count and potential dilution: 12,598,125 shares were outstanding at December 31, 2021; subsequent awards included 549,064 options and 403,522 restricted stock units granted in February 2022.